Kadimastem to Present Interim Results of Cohort A of Its Phase 1/2a Clinical Trial in ALS at the 7th International Stem Cell Meeting, in Tel-Aviv,…
By daniellenierenberg
NESS ZIONA, Israel, Nov. 11, 2019 /PRNewswire/ --Kadimastem Ltd.(TASE: KDST),a clinical stage cell therapy company, today announced that it will present the interim results of Cohort A of its ongoing Phase 1/2a Clinical Trial in ALS (as published in Company's press release) at the 7th International Stem Cell Meeting, to be held on November 12-13 at the Dan Panorama Hotel in Tel Aviv, Israel.
The International Stem Cell Meeting, hosted by the Israel Stem Cell Society, is a highly reputed conference, participated by international world leaders in stem cell research.
Presentation Details:
Title: "FIRST IN HUMAN CLINICAL TRIALS WITH HUMAN ASTROCYTES AS A NOVEL CELL THERAPY FOR THE TREATMENT OF ALS"
Session:ONGOING CLINICAL TRIALS WITH CELL THERAPY
Presenter:Arik Hasson, PhD, Executive VP, Research and Development, Kadimastem
Date:Wednesday, November 13, 2019
Time:1:50 pm Israel
Location: Dan Panorama Hotel, Tel Aviv, Israel
Rami Epstein, CEO of Kadimastem, stated: "We are pleased to share these results with global leaders in the cell therapy and stem cells industry,demonstrating the potential of AstroRx, our astrocyte-based cell therapy product,to bring treatment to ALS patients, and possibly other neurodegenerative diseases. We look forward to further share data of this ongoing trial, with final results of cohort A expected by year-end 2019and results of cohort B expected in Q3, 2020."
About the Phase 1/2a ALS Clinical Trial
The Phase 1/2a trial is an open label, dose escalating clinical study to evaluate the safety, tolerability and preliminary efficacy of AstroRxcells in patients with ALS. The trial is expected to include 21 patients and is being conducted at the Hadassah Medical Center, Jerusalem, Israel. The primary endpoints of the trial are safety evaluation and tolerability of a single administration of allogeneic astrocytes derived from human Embryonic Stem Cells (hESC), administered in escalating low, medium and high doses (100x106, 250x106, and 500x106 cells, respectively). The medium dose will also be administered in 2 consecutive injections separated by an interval of ~60 days. Secondary end points include efficacy evaluation and measurements. Treatment is administered in addition to the appropriate standard-of-care.
About AstroRx
AstroRx is a clinical grade cell therapy product developed and manufactured by Kadimastem in its GMP-compliant facility, containing functional healthy astrocytes (nervous system support cells) derived from human Embryonic Stem Cells (hESC) that aim to protect diseased motor neurons through several mechanisms of action. The Company's technology enables the injection of AstroRxcells into the spinal cord fluid of patients suffering from Amyotrophic Lateral Sclerosis (ALS) with the goal of supporting the malfunctioning cells in the brain and spinal cord, in order to slow the progression of the disease and improve patients' quality of life and life expectancy. AstroRxhas been shown to be safe and effective in preclinical studies. AstroRxhas been granted orphan drug designation by the FDA.
About ALS
Amyotrophic Lateral Sclerosis (ALS) is a rapidly progressive fatal neurodegenerative disease causing disfunction in the upper and lower motor nerves that control muscle function. ALS leads to muscle weakness, loss of motor function, paralysis, breathing problems, and eventually death. The average life expectancy of ALS patients is 2-5 years. According to the ALS Therapy Development Institute, it is estimated that there are approximately 450,000 ALS patients worldwide of which 30,000 reside in the US. According to the ALS Foundation for Life, the annual average healthcare costs of an ALS patient in the US are estimated at US$ 200,000. Thus, the annual healthcare costs of ALS patients in the US alone amount to US$ 6 Billion.
About Kadimastem
Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf" allogeneic proprietary cell products based on its platform technology for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into clinical grade functional cells. AstroRx, the Company's lead program, is a clinical-grade astrocyte cell therapy for the treatment of ALS, currently undergoing a Phase 1/2a clinical trial. In addition, preclinical trials are ongoing with the Company's IsletRx pancreatic functional islet cells for the treatment of insulin dependent diabetes. Kadimastem was founded by Prof. Michel Revel, CSO of the Companyand Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Prof. Revel received the Israel Prize for the invention and development of Rebif, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST).
Company Contacts:Yossi Nizhar, CFOy.nizhar@kadimastem.com+972-73-797-1613
Investor and Media Contact:Meirav Gomeh-Bauermeirav@bauerg.com+972-54-476-4979
Global Media Contact:Dasy (Hadas) MandelDirector of Business Development, Kadimastemd.mandel@kadimastem.com+972-73-797-1613
SOURCE Kadimastem
- Bone marrow mesenchymal stem cells modulate miR-202-3p to suppress neuronal apoptosis following spinal cord injury through autophagy activation via... - December 9th, 2024
- Stem Cells Reveal Secret to Beneficial Proteins for mRNA Therapy - An Interview with Neuroscientist Prof. Dr. Antal Ngrdi - Szegedi Tudomnyegyetem - December 9th, 2024
- Much-anticipated human trial aiming to repair spinal cord damage about to begin - ABC News - October 21st, 2024
- The Science Of Health: Are Spinal Cord Injuries Irreversible? Know Science Advances That Can Cure Them In The Future - ABP Live - October 16th, 2023
- Evaluating the Growth Prospects of the Global Nerve Repair & Regeneration Market at a CAGR of 6.5% | Emergen - EIN News - April 21st, 2023
- Regenerative Therapies Market is Set to Grow at a CAGR of 8.7% by 2033, Propelled by Advancements in - EIN News - March 17th, 2023
- Kadimastem Submits IND Application to the FDA for its Phase IIa Clinical Trial with AstroRx for the Treatment of ALS - Marketscreener.com - February 21st, 2023
- My Back Is All F*cked Up 55-Year-Old Joe Rogan Curses at Worst Jiu-Jitsu for Painful Health Condition - EssentiallySports - February 21st, 2023
- Brain and Spinal Cord Tumors: Hope Through Research - January 3rd, 2023
- 14.3 The Brain and Spinal Cord Anatomy & Physiology - January 3rd, 2023
- Stem Cell Therapy for Spinal Cord Injury - PubMed - January 3rd, 2023
- Spinal cord injury - Diagnosis and treatment - Mayo Clinic - December 25th, 2022
- Spinal Cord Injury: Hope Through Research | National Institute of ... - December 1st, 2022
- Stem cell controversy - Wikipedia - October 13th, 2022
- Stem Cells Australia | Australian research, stem cell treatments and ... - October 13th, 2022
- The eye and stem cells: the path to treating blindness - October 13th, 2022
- World's first stem cell treatment for spina bifida delivered during fetal surgery - UC Davis Health - October 13th, 2022
- Fighting One Disease or Condition per Day - Daily Kos - October 13th, 2022
- UPDATE: NurExone Signs Letter of Intent with Nanometrix for Its Exosome and Cargo Molecular Profiling AI-Driven Technology - Yahoo Finance - October 13th, 2022
- Global Cell Therapy Market Report (2022 to 2028) - Featuring Thermo Fisher Scientific, MaxCyte, Danaher and Avantor Among Others -... - October 13th, 2022
- Horizon Therapeutics plc Announces New UPLIZNA (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS... - October 13th, 2022
- Physiology, Spinal Cord - StatPearls - NCBI Bookshelf - October 5th, 2022
- IMAC Holdings, Inc. Announces Completion of Third Cohort of its Phase 1 ... - October 5th, 2022
- Revolutionary Jab that Could Repair Spinal Cord Injuries Developed by Scientists - Good News Network - October 5th, 2022
- How the 'Love Hormone' Oxytocin May Help Heal Heart Muscles - Healthline - October 5th, 2022
- Unlocking the Mysteries of Brain Regeneration Groundbreaking Study Offers New Insight - SciTechDaily - October 5th, 2022
- In Conversation: How to understand chronic pain - Medical News Today - October 5th, 2022
- New drug could cure aggressive brain cancer stopping tumours in their tracks... - The US Sun - September 27th, 2022
- Rehabilitating spinal cord injury and stroke with graphene and gaming - Nanowerk - September 19th, 2022
- Induced Pluripotent Stem Cells Market Reaches at a CAGR of 8.0% in the Forecast Periods [2021-2031] - BioSpace - September 19th, 2022
- Axolotls can regenerate their brains - Big Think - September 19th, 2022
- IMAC Holdings, Inc. Announces Completion of Third Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the... - September 11th, 2022
- Spinal Muscular Atrophy: Causes and importance of early diagnosis for proactive management - Firstpost - September 11th, 2022
- Increasing Road Accidents and Fall Injuries among Aged Population Primarily Driving Need for Orthopedic Navigation Systems: Fact.MR Analysis - Yahoo... - September 3rd, 2022
- Culture of human nasal olfactory stem cells and their extracellular vesicles as advanced therapy medicinal products - Newswise - August 10th, 2022
- Curious kids: what is inside teeth? - The Conversation - August 10th, 2022
- Human placental mesenchymal stem cells derived exosomes improved functional recovery via attenuating apoptosis and increasing axonal regeneration... - August 2nd, 2022
- How the Regenerative Properties of Glioblastoma Can Be Terminated - Gilmore Health News - August 2nd, 2022
- New TSXV listing looks to address the $3B spinal cord injury treatment market (NRX.V) - FXStreet - July 25th, 2022
- Human iPSC co-culture model to investigate the interaction between microglia and motor neurons | Scientific Reports - Nature.com - July 25th, 2022
- Negligence in treatment of diseases like glioblastoma can be fatal, seminar told - The News International - July 25th, 2022
- What lab-grown cerebral organoids are revealing about the brain - New Scientist - July 25th, 2022
- Innovative Therapies, Care Equity Highlight 2022 ASCO Annual Meeting - Targeted Oncology - July 16th, 2022
- Global Stem Cell Manufacturing Market Value Projected To Reach USD 21.71 Billion By 2029, Registering A CAGR Of 9.1% - Digital Journal - July 16th, 2022
- Stem Cell Therapy Market Is Expected To Reach USD 455.61 Billion By 2027 At A CAGR Of 16 percent By Forecast 2027 Says Maximize Market Research (MMR)... - June 30th, 2022
- This startup wants you to have a personal stem cell stash - Freethink - June 30th, 2022
- Parents of 12-Year-Old Boy Praying for a Miracle, Appealing UK Judge's Decision to Remove Life Support - CBN.com - June 30th, 2022
- The end of Roe v. Wade affects more than just abortion - Vox.com - June 30th, 2022
- Horizon Therapeutics plc Submits Regulatory Filing for UPLIZNA (inebilizumab) in Brazil - Business Wire - June 20th, 2022
- Effect of Electrical Stimulation on Spinal Cord Injury: In Vitro and In Vivo Analysis - Newswise - June 11th, 2022
- First-of-its-Kind Stem Cell and Gene Therapy Highlighted at Annual Stem Cell Meeting - Newswise - June 11th, 2022
- UK Judge to Decide if 12-Year-Old Will Be Removed from Life Support, Parents Beg for More Time to Heal - CBN.com - June 11th, 2022
- 'This is my life, and I'll try anything to save it': Woman with MS raising funds for treatment - The Brandon Sun - May 29th, 2022
- Racing Thoughts: Quadriplegic Man Drives Race Car With His Brain - Newsy - May 29th, 2022
- Physical therapy for vertigo: Exercises, benefits, and more - Medical News Today - May 29th, 2022
- Researchers find new function performed by almost half of brain cells - Medical News Today - May 13th, 2022
- Texas Family Fights to Access $2.1 Million Treatment for Baby - NBC 5 Dallas-Fort Worth - May 13th, 2022
- Severe COVID-19 may cause cognitive deficits equivalent to 20 years of aging - Medical News Today - May 13th, 2022
- Stem Cell Magic: 5 Promising Treatments For Major Medical Conditions - Study Finds - April 29th, 2022
- Neural Stem Cell Therapy For Spinal Cord Injury To Tap Into The Potential Of Stem Cells - Optic Flux - April 15th, 2022
- Still Blooming: Sams mission to raise money for spinal cord injury research - 7NEWS - April 15th, 2022
- Lineage and Cancer Research UK Announce Completion of Patient Enrollment in Phase 1 Clinical Study of VAC2 for the Treatment of Non-small Cell Lung... - April 15th, 2022
- Lineage Announces Pipeline Expansion to Include Auditory Neuronal Cell Therapy for Treatment of Hearing Loss - Galveston County Daily News - March 22nd, 2022
- COVID-19: Even mild to moderate infection may cause brain anomalies - Medical News Today - March 22nd, 2022
- Scots mum with MS says 50k treatment abroad is 'last hope' of halting disease - Daily Record - January 18th, 2022
- Mending the gap: U of T's Molly Shoichet joins team developing new treatments for spinal cord injuries - News@UofT - January 18th, 2022
- Spinal Cord Injury Information Page | National Institute ... - January 3rd, 2022
- Dancing molecules successfully repair severe spinal cord ... - January 3rd, 2022
- Best 2021 Medical Breakthroughs And Treatments to Beat Cancer, Alzheimer's, Diabetes & More - Good News Network - January 3rd, 2022
- Global Regenerative Medicine Market is Expected to Reach USD 57.08 Billion by 2027, Growing at a CAGR of 11.27% Over the Forecast Period. -... - December 23rd, 2021
- Scientists unravel a gene function that helps the genesis of neurons - Research Matters - December 23rd, 2021
- The 10 Most Compelling Research Stories of 2021 PharmaLive - PharmaLive - December 23rd, 2021
- 2021: The year in review | YaleNews - Yale News - December 23rd, 2021
- Polymyositis Pipeline to Progress with New and Emerging Drugs for Treatment, Analyzes DelveInsight - GlobeNewswire - December 10th, 2021
- Cell and Gene Therapy Market to reach US$ 47,095.2 Mn by end of 2028, Says Coherent Market Insights - PRNewswire - November 22nd, 2021
- From asthma to cancer to infertility, the new treatments, jabs and meds making us healthier... - The Sun - November 22nd, 2021
- Improving motor neuron-like cell differentiation of hEnSCs by the combination of epothilone B loaded PCL microspheres in optimized 3D collagen... - November 8th, 2021
- Akiko Nishiyama Explains the Many Strengths of a Degree in Physiology and Neurobiology - UConn Today - UConn Today - October 28th, 2021
- Team finds way to enhance stem cell therapy for CNS injuries - BioPharma-Reporter.com - October 28th, 2021
- 'Rogue' antibodies found in brains of teens with delusions and paranoia after COVID-19 - Livescience.com - October 28th, 2021